Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,082 public trials 2,050 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT02665650

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • University of Alabama Comprehensive Cancer Center Birmingham, Alabama, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Ronald Reagan UCLA Medical Center Los Angeles, California, United States
View all 18 locations
View Trial Details
Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

NCT00987493

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Kantonsspital Baden Baden, Switzerland
  • Universitaetsspital Basel Basel, Switzerland
  • St. Claraspital AG Basel, Switzerland
  • Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli Bellinzona, Switzerland
View all 16 locations
View Trial Details
Completed

Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma

NCT00227695

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Clinical Center - Institute of Hematology São Paulo, Brazil
  • Istituto Europeo di Oncologia IEO Milan, Italy
  • Clinical Center Skopje Skopje, North Macedonia
  • Clinical Center of Serbia Belgrade, Serbia
View all 26 locations
View Trial Details
Completed

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

NCT00392691

Conditions
Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +37 more
Locations
  • Kantonsspital Aarau Aarau, Switzerland
  • Saint Claraspital AG Basel, Switzerland
  • Universitaetsspital-Basel Basel, Switzerland
  • Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli Bellinzona, Switzerland
View Trial Details
Completed

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

NCT00544219

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • European Institute of Oncology Milan, Italy
  • Hirslanden Klinik Aarau Aarau, Switzerland
  • Kantonspital Aarau Aarau, Switzerland
  • Kantonsspital Baden Baden, Switzerland
View all 19 locations
View Trial Details
Completed

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

NCT01539512

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • Arizona Oncology Associates Tucson, Arizona, United States
  • University of California, San Diego- Moores Cancer Center La Jolla, California, United States
  • Ventura County Hematology Oncology Specialists Oxnard, California, United States
View all 72 locations
View Trial Details

Related conditions